Financial Data and Key Metrics Changes - Net sales increased by 4.6% to $346.6 million, primarily driven by $22 million of inorganic sales from the acquisition of UW Solutions [10][11] - Adjusted EBITDA margin decreased to 9.9%, primarily due to a less favorable mix and higher aluminum costs [11] - Adjusted diluted EPS declined to $0.56, driven by lower adjusted EBITDA, higher interest expense, and a higher adjusted effective tax rate [11][12] Business Line Data and Key Metrics Changes - Metals segment net sales declined by 3.4%, with adjusted EBITDA margin decreasing to 7.3% due to a less favorable mix and higher aluminum costs [11][12] - Services segment achieved a 7.6% increase in net sales, marking its fifth consecutive quarter of growth, although adjusted EBITDA margin decreased to 5.7% due to higher tariff expenses [12] - Glass segment net sales declined, with adjusted EBITDA margin moderating due to reduced volume from lower end market demand [12] - Performance Surfaces segment saw net sales increase, driven by inorganic sales from UW Solutions, but adjusted EBITDA margin declined to 18.8% due to lower margins from UW Solutions [12] Market Data and Key Metrics Changes - The revenue pipeline for Glass is improving, positioning the segment for growth beginning in Q3 and Q4 [7][10] - Metals showed sequential improvement from Q4, with expectations for continued improvement in Q2 [6][11] Company Strategy and Development Direction - The company is focusing on operational improvements and cost mitigation strategies, particularly through Project Fortify Phase two, which is expected to drive annualized savings of $13 million to $15 million [6][10] - The company is actively pursuing M&A opportunities to diversify its business mix and enhance growth prospects [8][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in building momentum for the second half of the fiscal year, driven by improvements in metals, growth in glass revenues, and strong organic growth in Performance Surfaces [17] - The company raised its fiscal year outlook for net sales and adjusted diluted EPS, expecting net sales in the range of $1.4 billion to $1.44 billion and adjusted diluted EPS between $3.8 and $4.2 [14][17] Other Important Information - The company is experiencing challenges due to increased tariffs but is implementing successful mitigation plans [6][10] - The balance sheet remains strong, with a consolidated leverage ratio of 1.6 and no near-term debt maturities [13] Q&A Session Summary Question: Can you elaborate on the glass business and the revenue pipeline? - Management noted good visibility six months out and mentioned a pivot to smaller jobs to fill gaps due to market softness, with improved quote activity and award rates [22][24] Question: What is the outlook for segment margin targets? - Management indicated that metals and services face headwinds due to tariffs, and while they hope to reach the bottom of their target ranges, it may be challenging in the first half [28][30] Question: What is driving the sequential improvement in the metals segment? - Management highlighted operational improvements and regaining customer confidence as key factors driving sales and margin improvements [40][42] Question: What is the status of Project Fortify Phase two? - Minimal savings were seen in Q1, with more expected to materialize in Q2, particularly following the closure of a Canadian facility [45][47] Question: Can you quantify the EPS impact from tariffs in Q1? - The impact was initially estimated at $0.45 to $0.55, but was updated to $0.35 to $0.45 for the full year, with a favorable trend noted in Q1 [48][50] Question: How is the M&A pipeline being affected by the current environment? - Management stated that while M&A activity has slowed due to macro issues, they continue to focus on strategic targets identified over the past two years [63][65]

Accelerating The Creation Of Semiconductors Corporate Overview Charlie Janac CEO Nick Hawkins CFO November 2024 1 © 2024 Arteris, Inc. Disclaimer This presentation and the accompanying oral presentation have been prepared by Arteris, Inc. ("Arteris IP" or "the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Arteris IP or any officer, director, employ ...

Investor Presentation March 28, 2025 CAUTIONARY STATEMENT This presentation contains forward-looking statements in which Stratus discusses factors it believes may affect its future performance. Forward-looking statements are all statements other than statements of historical fact, such as plans, projections or expectations related to inflation, interest rates, tariffs, supply chain constraints, Stratus' ability to pay or refinance its debt obligations as they become due, availability of bank credit, Stratus ...

INVESTOR PRESENTATION NOVEMBER 15, 2024 Avalon Princeton Circle Princeton, NJ IMPORTANT INFORMATION See Appendix for information about forward-looking statements and definitions and reconciliations of non-GAAP financial measures and other terms. For the reasons described in the referenced forward-looking statements our historical results may not be indicative of future results. The projections for AvalonBay Communities, Inc. included in this presentation were originally included in its November 4, 2024, ear ...

Sustainable Long-Term Growth from Commercial Pharmaceutical Assets Nasdaq: ASRT May 2025 Disclaimers The statements in this communication include forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking statements speak only as of the date they are made or as of the dates indicated in the statements and should not be relied upo ...

1 © 2025 Artivion, Inc. Corporate Overview May 2025 FORWARD-LOOKING STATEMENT These statements include our belief that we have driven and can continue to drive sustained double digit revenue growth and 2x+ EBIDTA Growth as a result of our highly differentiated highly defendable base business, our high growth stent graft business and our leverageable global infrastructure; our estimated total addressable markets for preservation services (human tissue), mechanical heart valves, and surgical sealants are $150 ...

Enerpac Tool Group (EPAC) Q3 2025 Earnings Call June 27, 2025 08:30 AM ET Company Participants Travis Williams - Senior Director of Investor RelationsPaul Sternlieb - CEO, President & DirectorDarren Kozik - EVP & CFODaniel Moore - Director of ResearchSam Karlov - Research Associate Conference Call Participants Tom Hayes - MD & Senior Equity AnalystSteve Silver - Senior Equity Research Analyst Operator Ladies and gentlemen, thank you for standing by. Welcome to the Enerpac Tool Group's Third Quarter Fiscal t ...

Summary of BioCryst Pharmaceuticals (BCRX) Conference Call Company Overview - **Company**: BioCryst Pharmaceuticals (BCRX) - **Event**: Conference call regarding the sale of the European business - **Date**: June 27, 2025 Key Points Industry and Company Strategy - BioCryst Pharmaceuticals is focused on creating value through three main drivers: 1. Establishing ORLIDEAL as a global market leader with a target of $1 billion in peak revenue [5] 2. Launching new products from its pipeline to ensure sustainable growth [6] 3. Strengthening financial independence and profitability to facilitate business development opportunities [6] Sale of European Business - BioCryst announced the sale of its European business to NeoPharmad Gentile (NG) for $250 million, which includes the PEOPLE and Orlodayo products in Europe [5][6] - The deal is expected to provide up to $14 million in future milestones related to sales in Central and Eastern Europe [7] - The European business accounts for less than 10% of global sales and has lower margins compared to other regions [7] Financial Impact - The upfront cash from the sale will be used to pay off all remaining term debt, saving approximately $70 million in interest payments over the loan's remaining life [8] - By the end of 2027, BioCryst anticipates having nearly $700 million in cash with no term debt, an improvement of about $400 million in net cash from previous projections [8] - The transaction is expected to significantly enhance profitability by focusing on higher-margin business primarily in the U.S. [8] Royalty Structure - The agreement allows BioCryst to benefit from European revenue in global royalty calculations, with NG responsible for royalties from European sales [10] - This structure will help reduce future royalty payments significantly once certain thresholds are reached [10] Future Growth and Pipeline - BioCryst is excited about two main pipeline programs: 17,725 for Netherlands and oral staff for DME, and is in a stronger financial position to fund these programs [23] - The company does not plan to expand its sales force but aims to optimize performance with the existing team of 40 representatives [24] Business Development Strategy - BioCryst is looking to acquire additional products, particularly in the rare disease space, with a focus on later-stage programs [32] - The company aims to be a consolidator in the U.S. market, similar to NG's strategy in Europe [33] Regulatory Updates - The PDUFA date for the pediatric Orlodayo NDA has been extended to December 12 due to a major amendment, but the company remains confident about the product's potential [51] Cost Savings - The sale is expected to result in a minimum of $50 million in annual operating expense savings, effective after the transaction closes [61] Additional Insights - The transaction aligns with BioCryst's strategy to enhance financial strength and operational efficiency [13] - The company emphasizes the importance of cash flow and profitability, particularly from the U.S. market, which is seen as the most valuable contributor to the company's financial health [26] This summary encapsulates the key discussions and strategic insights from the BioCryst Pharmaceuticals conference call, highlighting the company's focus on financial strength, strategic sales, and future growth opportunities.

Financial Data and Key Metrics Changes - Enerpac's revenue increased by 6% year-over-year to $159 million in Q3 2025, marking record revenue since the company's relaunch in 2019 [5][7] - Organic growth, adjusted for foreign exchange and the acquisition of DTA, was 2% [7] - Adjusted EBITDA increased by 3.4%, with a margin decline of 50 basis points year-over-year to 25.9% [13] - Adjusted earnings per share rose by 9% to $0.51, driven by higher earnings and a lower effective tax rate [14] Business Line Data and Key Metrics Changes - The IT and S business saw a 1.5% organic revenue increase year-over-year, with product sales growing by 1% and services by 3% [7][8] - Cortland Biomedical reported a 19% growth, driven by strong performance in diagnostics, bioprocessing, and robotic surgery [8] - The Americas region experienced high single-digit organic growth, particularly in aerospace and infrastructure sectors [9] Market Data and Key Metrics Changes - The APAC region achieved mid single-digit growth, with notable strength in heavy lifting technology and major rail projects in Thailand, Japan, and The Philippines [10] - The EMEA region faced a high single-digit decline, primarily due to a drop in the heavy lifting technology business, although infrastructure and defense markets showed strength [11] Company Strategy and Development Direction - The company is focused on advancing its innovation strategy and has invested in a new innovation lab to enhance R&D capabilities [21] - Enerpac aims to remain price cost neutral amid tariff impacts and is actively managing expenses to align with market conditions [19][20] - The acquisition of DTA is expected to enhance Enerpac's product offerings and operational capabilities, with strong order growth anticipated [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed caution entering Q4 due to economic and geopolitical uncertainties but remains confident in outperforming industrial peers [6] - The company is monitoring customer reactions to tariffs and macroeconomic conditions, noting no significant project cancellations [28][29] - Future revenue guidance for fiscal 2025 remains at $610 million to $625 million, with expectations to deliver towards the lower half of the range [14] Other Important Information - Gross profit margin declined by 140 basis points year-over-year to 50.4%, attributed to service project mix and the inclusion of DTA [11][12] - Net debt stood at $50 million, with a net debt to adjusted EBITDA ratio of 0.4, indicating a strong balance sheet [15] - The company repurchased approximately 330,000 shares for $14 million during the quarter [16] Q&A Session Summary Question: Customer reactions to tariffs and macro uncertainty - Management noted that while customers are cautious, there have been no significant project cancellations, and underlying investment needs remain [28][29] Question: Revenue pull-forward in anticipation of tariffs - Management indicated there was some minor buying activity but nothing significant [30] Question: Details on restructuring actions and anticipated cost savings - Restructuring included severance and a noncash lease impairment charge, aimed at improving efficiency and cost structure [32][33] Question: Impact of pricing actions taken - Pricing actions were implemented in March and May, with expected positive impacts in the upcoming quarter [39] Question: North American performance drivers - Management highlighted diversified end markets, with aerospace and infrastructure contributing to high single-digit growth [40][41] Question: Outlook for the wind market - Management remains optimistic about the wind market, noting ongoing projects and favorable demand profiles [43][44] Question: M&A appetite in the current environment - Management confirmed continued focus on M&A as part of growth strategy, with active engagement in discussions [46][47] Question: Tariff impact on DTA's cross-selling ability - Management acknowledged that DTA products would be subject to tariffs but noted strong demand from US customers [57][58] Question: Context around the new innovation lab - The new lab is expected to significantly reduce time to market for new products, enhancing overall innovation capabilities [66][67]

Strategic Acquisition of Sallyport Commercial Finance Investor Presentation November 1, 2024 Nasdaq: NRIM 1 Forward Looking Statement This investor presentation may contain "forward-looking statements" as that term is defined for purposes of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are, in effect, management's attempt to predict future events, and thus are subject to various risks and uncertainties. Readers should not place undue reliance on forward-looking statements ...